Overview

An Open-Label Phase I/II Clinical Study of PT-112 in Combination With Docetaxel in Subjects With Advanced Solid Tumor in a Phase I Dose Escalation Study and in Subjects With Non-Small Cell Lung Cancer (NSCLC) in a Phase II Dose Confirmation Study

Status:
Unknown status

Trial end date:
2019-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to test PT-112 in Combination with Docetaxel in Subjects with Advanced Solid Tumor in a Phase I Dose Escalation Study and in Subjects with Non-Small Cell Lung Cancer.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

SciClone Pharmaceuticals International (Cayman) Development Limited

Collaborators:

National Cheng-Kung University Hospital
Parexel

Treatments:

Docetaxel